Extended Data Table 3 Pharmacokinetic analysis of ketamine and its metabolites following ketamine-loaded AAL or free ketamine 1.5 mg/kg bolus intravenous administration

From: Acoustically activatable liposomes as a translational nanotechnology for site-targeted drug delivery and noninvasive neuromodulation

 

Units

Ketamine AAL (Mean ± SD)

Free Ketamine (Mean ± SD)

P-value AAL vs Free Ketamine

Ketamine

Cmax

ng/mL

2043.35 ± 203.59

789.20 ± 140.32

** 0.001

Tmax

m

1 ± 0

1 ± 0

NA

C0

ng/mL

4708.81 ± 720.06

1074.98 ± 138.67

* 0.010

t1/2

m

11.22 ± 2.52

8.82 ± 1.07

0.236

AUC0-t

ng/mL m

9269.64 ± 1023.11

6357.64 ± 1155.59

* 0.031

AUC0-∞

ng/mL m

10977.88 ± 703.92

7819.91 ± 1162.77

* 0.023

MRT0-t

m

4.04 ± 0.03

6.83 ± 0.09

*** 0.0001

MRT0-∞

m

9.19 ± 1.82

11.78 ± 1.16

0.118

VZ

L

0.52 ± 0.16

0.58 ± 0.12

0.68

Cl

L/m

0.032 ± 0.0025

0.045 ± 0.0038

* 0.011

VSS

L

0.30 ± 0.08

0.53 ± 0.093

* 0.031

Norketamine

Cmax

ng/mL

328.50 ± 8.24

58.87 ± 4.35

*** 0.00001

Tmax

m

1 ± 0

11.67 ± 7.64

0.136

C0

ng/mL

413.68 ± 37.18

31.21 ± 8.11

** 0.002

AUC0-t

ng/mL m

3271.82 ± 148.01

968.99 ± 93.43

*** 0.00008

MRT0-t

m

7.94 ± 0.38

10.44 ± 0.30

** 0.001

Hydroxynorketamine

Cmax

ng/mL

362.06 ± 37.21

128.06 ± 6.58

** 0.006

Tmax

m

2.83 ± 2.02

16.67 ± 5.77

* 0.041

C0

ng/mL

343.63 ± 60.90

28.30 ± 5.38

* 0.011

AUC0-t

ng/mL m

5548.76 ± 723.45

2045.42 ± 130.49

* 0.011

MRT0-t

m

9.40 ±0.16

10.89 ± 0.42

* 0.015

  1. Cmax: maximum concentration; Tmax: time of maximum concentration; C0: concentration extrapolated to t0; t1/2: half life; AUC0-t: area under the curve from 0 to last time point; AUC0-∞: area under the curve from 0 to infinity; MRT0-t: mean residence time from 0 to last time point; MRT0-∞: mean residence time from 0 to infinity; VZ: volume of distribution; Cl: clearance; VSS: volume of distribution at steady state; *: p < 0.05; **: p < 0.01; ***: p < 0.001.